| Biomarker ID | 553 |
| PMID | 20973404 |
| Year | 2010 |
| Biomarker | Cathepsin D |
| Biomarker Basis | Concentration Based (pmol/mL) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated (pmol/mL): (Controls: 4.85±1.35) Vs (Prostate Cancer: 9.2±1.75) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Inclue:- Downregulation of MTA-3 in ER-negative breast tumors,LKB1 signaling events,Ceramide signaling pathway,Validated nuclear estrogen receptor alpha network, Prolactin activation of MAPK signaling |
| Experiment | Control Vs Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | 50 patients as controls, 75 with BPH and 100 with Prostate Cancer were chosen for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | ELISA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CTSD |